Targeted treatment for metastatic renal cell carcinoma and immune regulation

Journal of B.U.ON.

Volumn 15, Issue 2, 2010, Pages 235-240

  Laschos, Konstantinos A ^a   Papazisis, K T ^a   Kontovinis, L F ^a   Kalaitzis, C ^b   Gianakopoulos, S ^b   Kortsaris, A H ^b   Touloupidis, S ^b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Immune regulation; Renal cancer; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TORICEL; UNCLASSIFIED DRUG;

ANGIOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; METASTASIS; MONOTHERAPY; REMISSION; REVIEW; T LYMPHOCYTE ACTIVATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INDOLES; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; PYRROLES; T-LYMPHOCYTES; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954412168     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Jernal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Beck SD, Patel MI, Snyder ME et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004; 11: 71-77.
3. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Path 2003; 27: 612-624. (Pubitemid 36514472)
4. Klimis T, Karvounis H. Renal cell carcinoma with rhabdoid features. Divergent differentiation of conventional (clear cell) carcinoma. J BUON 2008; 13: 433-436.
5. Motzer RJ, Mazumadar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540. (Pubitemid 29368255)
6. Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178: 1883-1887. (Pubitemid 47538608)
7. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320. (Pubitemid 23231974)
8. George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor and kidney cancer. N Engl J Med 2003; 349: 419-421. (Pubitemid 36910018)
9. Ferrara N, Kerbel R. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
10. Guermonprez P, Valladeau J, Zitvogel L et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-667. (Pubitemid 34293436)
11. Chaux P, Moutet M, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997; 72: 619-624. (Pubitemid 27356163)
12. Gabrilovich DI, Ciemik IF, Carbone DP. Dendritic cells in antitumor immune responses I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996; 170: 101-110.
13. Ohm JE, Shurin MR, Esche C et al. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999; 163: 3260-3268. (Pubitemid 29431827)
14. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103. (Pubitemid 26338628)
15. Takahashi A, Kono K, Ichihara F et al. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 2004; 53: 543-550. (Pubitemid 38680261)
16. Dikov MM, Ohm JE, Ray N et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005; 174: 215-222. (Pubitemid 40007407)
17. Fricke I, Mirza N, Dupont J et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007; 13: 4840-4848. (Pubitemid 47298146)
18. Ohm JE, Gabrilovich DI, Sempowski GD et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003; 101: 4878-4886.
19. Negrier S, Escudier B, Lasset C et al. Recombinant human IL-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-1278.
20. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417. (Pubitemid 30060482)
21. Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007; 110: 2468-2477. (Pubitemid 350174932)
22. Radulovic S, Bjelogrlic SK. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 2007; 12(Suppl 1): S151-S162.
23. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patient swim metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
24. Motzer RJ, Hutson TE, Tomczack P et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
25. Kontovinis LF, Papazisis KT, Touplikioti P et al. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009; 9: 82.
26. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 115-134.
27. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. (Pubitemid 350296300)
28. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. (Pubitemid 46849157)
29. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
30. Gabrilovich DI, Ishida T, Nadaf S et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963-2970. (Pubitemid 29493976)
31. Tamir A, Jordan WJ, Ritter M et al. Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity. Clin Exp Immunol 2005; 142: 471-480. (Pubitemid 41719843)
32. Melichar B, Koralewski P, Ravaud A et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-1476.
33. Cao W, Manicassamy S, Tang H et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3) K-mTOR-p70S6K pathway. Nat Immunol 2008; 9: 1157-1164.
34. Ko H, Hambly BD, Eris JM et al. Dendritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. Transpl Immunol 2008; 20: 99-105.
35. WoltmanAM, van der Kooij SW, Coffer PJ et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101: 1439-1445.
36. Ohtani M, Nagai S, Kondo S et al. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 2008; 112: 635-643.
37. Weichhart T, Costantino G, Poglitsch M et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565-577.
38. Van Cruijsen H, van der Veldt AA, Vroling L etal. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008; 14: 5884-5892.
39. Lenahan C, Cho D, Bissonnette A et al. Immunologic effects of sunitinib in renal cell carcinoma. J Clin Oncol 2008; 26 (Suppl): 14551 (abstr).
40. Finke J, Rini B, Ireland J, Rayman P et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14: 6674-6682.
41. Osada T, Chong G, Tansik R et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115-1124.
42. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002; 8: 2255-2257.
43. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
44. Franklin RA, Tordai A, Patel H et al. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J Clin Invest 1994; 93: 2134-2140.
45. Zhao W, Gu YH, Song R et al. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 2008; 22: 1226-1233. (Pubitemid 351833791)
46. Hipp MM, Hiff N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111: 5610-5620.
47. Rixe O, Billemont B, Izzedine H. Hypertension as apredictive factor of sunitinib activity. Ann Oncol 2007; 18: 1117. (Pubitemid 47050505)
48. Wolter P, Stefan C, Decallonne B et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 2008; 26 (Suppl): 5126 (abstr).
49. Eto M, Takeucbi A, Ohki T et al. In vitro and in vivo analysis of synergistic antitumor effects of interferon-α and sorafenib in renal cell carcinoma. J Clin Oncol 2008; 26 (Suppl): 16143 (abstr).
50. Tannik NM, Zurita AJ, Heymach JV et al. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 2008; 26(Suppl): 5093 (abstr).
51. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009; 27: 3225-3234.
52. Fyge G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696.
53. Klapper JA, Downey SG, Smith FO et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113: 293-301.
54. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141. (Pubitemid 41702632)
55. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132.
56. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial: Medical Research Council, Renal Cancer Collaborators. Lancet 1999; 353: 14-17.
57. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev: CD001425, 2005.
58. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001; 19: 148-154. (Pubitemid 32410348)
59. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296. (Pubitemid 34032623)
60. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24. (Pubitemid 46630489)
61. Szcylik C, Demkow T, Staehler M et al. Randomized phase III trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007; 25: 5025.
62. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (MRCC). J Clin Oncol 2008; 26(Suppl): 256S (abstr 5024).
63. Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007; 25(Suppl): 240S (abstr 5023).
64. Yang JC, Haworth L, Sherry RM et al. Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434. (Pubitemid 36910021)
65. Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized phase DJ study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25: 4536-4541.
66. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-912.